Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome

Wilhelmina G Leen; Corry M Weemaes; Marcel M Verbeek; Michèl A Willemsen; Jan J Rotteveel

doi:10.1016/j.pediatrneurol.2008.05.015

Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome

Pediatr Neurol. 2008 Sep;39(3):213-7. doi: 10.1016/j.pediatrneurol.2008.05.015.

Authors

Wilhelmina G Leen¹, Corry M Weemaes, Marcel M Verbeek, Michèl A Willemsen, Jan J Rotteveel

Affiliation

¹ Department of Pediatric Neurology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. [email protected]

PMID: 18725071
DOI: 10.1016/j.pediatrneurol.2008.05.015

Abstract

We describe 2 children with postinfectious opsoclonus-myoclonus syndrome. Although the patients initially responded to monotherapy with methylprednisolone, intravenous immunoglobulins, or rituximab, they manifested persistent neurologic deficits and relapsing signs. Treatment with rituximab in combination with intravenous immunoglobulin, however, resulted in significant longterm clinical improvement.

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived
Drug Therapy, Combination
Female
Humans
Immunoglobulins, Intravenous / administration & dosage
Immunoglobulins, Intravenous / therapeutic use*
Immunologic Factors / administration & dosage
Immunologic Factors / therapeutic use
Infant
Opsoclonus-Myoclonus Syndrome / drug therapy*
Opsoclonus-Myoclonus Syndrome / pathology
Recurrence
Rituximab
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Immunoglobulins, Intravenous
Immunologic Factors
Rituximab